These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 31028880)

  • 1. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease.
    Shi YC; Cai ST; Tian YP; Zhao HJ; Zhang YB; Chen J; Ren RR; Luo X; Peng LH; Sun G; Yang YS
    Genomics Proteomics Bioinformatics; 2019 Feb; 17(1):52-63. PubMed ID: 31028880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease.
    Shi Y; Li J; Cai S; Zhao H; Zhao H; Sun G; Yang Y
    Front Cell Infect Microbiol; 2023; 13():1205348. PubMed ID: 37662013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study.
    Castellani C; Singer G; Kashofer K; Huber-Zeyringer A; Flucher C; Kaiser M; Till H
    Front Cell Infect Microbiol; 2017; 7():444. PubMed ID: 29075620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
    Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
    Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota.
    Imhann F; Vich Vila A; Bonder MJ; Lopez Manosalva AG; Koonen DPY; Fu J; Wijmenga C; Zhernakova A; Weersma RK
    Gut Microbes; 2017 Jul; 8(4):351-358. PubMed ID: 28118083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary microbiota composition before and after use of proton pump inhibitors in patients with laryngopharyngeal reflux: a self-control study.
    Cui X; Yin L; Zhang Y; Jiang X; Li L; Bi X
    BMC Oral Health; 2024 Oct; 24(1):1194. PubMed ID: 39379876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
    Kim JW; Jeong Y; Park SJ; Jin H; Lee J; Ju JH; Ji GE; Park SH
    Rheumatology (Oxford); 2021 Feb; 60(2):708-716. PubMed ID: 32789440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial.
    Singh G; Haileselassie Y; Briscoe L; Bai L; Patel A; Sanjines E; Hendler S; Singh PK; Garud NR; Limketkai BN; Habtezion A
    Clin Nutr ESPEN; 2022 Feb; 47():70-77. PubMed ID: 35063245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients.
    Li XB; Chu XJ; Cao NW; Wang H; Fang XY; Fan YG; Li BZ; Ye DQ
    BMC Microbiol; 2022 Apr; 22(1):117. PubMed ID: 35477382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors.
    Amir I; Konikoff FM; Oppenheim M; Gophna U; Half EE
    Environ Microbiol; 2014 Sep; 16(9):2905-14. PubMed ID: 24112768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy.
    Kikuchi H; Fukuda S; Koike T; Shimodaira Y; Watanabe K; Saito M; Nakagawa K; Hatta W; Masamune A; Iijima K
    Esophagus; 2021 Apr; 18(2):380-387. PubMed ID: 32737802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
    Gyawali CP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
    Freedberg DE; Kim LS; Yang YX
    Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.